Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Shares Outstanding (Weighted Average) (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Shares Outstanding (Weighted Average) data on record, last reported at $10.7 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 105.61% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, up 105.61%, while the annual FY2025 figure was $10.7 million, 105.61% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $10.7 million in Q4 2025 per VRCA's latest filing, up from $9.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $94.8 million in Q1 2025 and bottomed at $4.7 million in Q2 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $29.7 million, with a median of $27.5 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 89.89% in 2024, then skyrocketed 105.61% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $27.0 million in 2021, then rose by 26.32% to $34.2 million in 2022, then skyrocketed by 32.72% to $45.3 million in 2023, then tumbled by 88.57% to $5.2 million in 2024, then surged by 105.61% to $10.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $10.7 million in Q4 2025, $9.5 million in Q3 2025, and $9.5 million in Q2 2025.